France, a leader in the bioproduction of biomedicines
The French bioproduction sector is extremely buoyant, marked by massive industrial investments and unprecedented collective mobilization. Between 2020 and 2024, €6.3 billion was committed to developing new production capacity. This growth is supported by initiatives, such as the National Bioproduction and Biomedicines Day, which brought together 229 structures around 28 events in 2024.
The ‘France 2030’ plan: A promising future
The “France 2030” plan aims to position France as a global leader in biomanufacturing. This ambitious plan includes strategic investments to strengthen production capacity, attract talent and simplify regulations. The aim is to create an ecosystem conducive to innovation and competitiveness, building on strong partnerships between public and private stakeholders.
France BioLead: A key player in the transformation
France BioLead plays a central role in this dynamic, uniting industry players and promoting French biomanufacturing internationally. Their France BioLead Connect platform is a resource and information center, facilitating collaborations and exchanges between BioTech and industrial key players. In 2025, France BioLead will continue to strengthen synergies and remove regulatory barriers to fast-track the sector’s growth.
Key statistics on drug bioproduction in France
- Four percent of pharmaceutical products marketed worldwide are biomedicines, but they amount to 30% of the pharmaceutical industry’s total revenues.
- In France, 132 businesses are producing biomedicines, with 587 biomedicines in development.
- France is currently producing eight biomedicines within its own territory.
- “France 2030” aim: to produce 20 biomedicines by 2030.
- The global biotherapeutics market is expected to reach €320 billion by 2025.
“The bioproduction of biomedicines is a revolution for the healthcare industry and the daily lives of patients. By uniting all the key players in the sector, we can make France a European leader and restore our independence and sovereignty in this field” explains Laurent Lafferrère, Chief Economic Officer at France BioLead
A human and collective adventure
The success of French bioproduction relies on collective commitment and a shared vision. By working together, France can build a strong, innovative and European-oriented sector. Co-construction initiatives, such as the workshops with France Biotech, are essential to creating the conditions for successful and lasting collaboration.
French bioproduction is booming, driven by strategic investments and collective mobilization. The “France 2030” plan and France BioLead initiatives are essential levers for positioning France as a global leader in bioproduction. Together, we can build a promising future for French healthcare abroad.